Daily versus pulse oral itraconazole for tinea capitis in children
Official title: Comparative Clinicomycologic and Dermoscopic Study Between Daily and Pulse Therapy of Oral Itraconazole in Tinea Capitis in Children
Run by Alexandria University · NCT07184203 · Data updated 2026-11-12
This trial will test whether daily (continuous) or pulse oral itraconazole works better to clear tinea capitis in children aged 5 to 18.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 5 Years to 18 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Alexandria University Academic / other |
| Locations | 1 site (Alexandria) |
| Status | Recruiting |
| Started | March 9, 2025 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | September 19, 2025 |
| Trial ID | NCT07184203 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 5 to 18 with confirmed tinea capitis who weigh at least 20 kg and have no contraindications to itraconazole or other scalp disease are ideal candidates.
✕Probably not a fit
Children with contraindications to itraconazole, associated scalp diseases, or weighing less than 20 kg are unlikely to benefit or be eligible for this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study compares continuous daily oral itraconazole with pulse oral itraconazole in children aged 5–18 who have tinea capitis. Participants receive itraconazole by one of the two dosing schedules and are followed for clinical, mycological, and dermoscopic outcomes to determine treatment response. Children with contraindications to itraconazole, associated scalp disease, or weighing less than 20 kg are excluded. The trial is conducted at the Faculty of Medicine, Alexandria University, with enrollment limited to patients able to attend site visits there.
Why it matters
Potential benefit: If successful, the study could identify a dosing schedule that clears infection faster or with fewer side effects, making treatment easier for children.
How similar studies have gone: Pulse and continuous itraconazole regimens have been used for other superficial fungal infections and in adults, but direct pediatric head-to-head data for itraconazole in tinea capitis are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: • Tinea capitis patients with ages ranging from 5 to 18 year Exclusion Criteria: * Patients with contraindications to itraconazole * Patients with associated scalp disease. * Patients weighing less than 20 Kg.
Where it's running
-
Faculty of Medicine
Alexandria, Egypt Recruiting
Study contacts
- Study coordinator: Marina K Aioub
- Email: marinaaioub10@gmail.com
- Phone: 00201223805043
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Terbinafine dosing and blood levels in children with tinea capitis
This study will test how oral terbinafine is processed in children aged 2–18 with tinea capitis and whether the weight-based dosing is safe and effective.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.